Therefore, due to increasing treatment options, there is a need to better explore inflammatory response biomarkers, such as IL-6, CRP, and sCD40L, which have the potential to be useful in CRC prognosis [4,25,28]. This evidence concerns the gene IL6 and colorectal carcinoma.